 Connection
Robert Jotte to Quinazolines
This is a "connection" page, showing publications Robert Jotte has written about Quinazolines.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.372 |
|
|
|
-
Carneiro BA, Jotte RM, Gabrail NY, Wentzel K, Huang F, Chaturvedi S, Weispfenning A, Hiemeyer F, Morcos PN, Mongay Soler L, Childs BH, Hansen AR. Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors. Cancer Res Commun. 2025 03 01; 5(3):444-457.
Score: 0.196
-
Jotte RM, Von Hoff DD, Braiteh F, Becerra CR, Richards DA, Smith DA, Garbo L, Stephenson J, Conkling PR, Robert-Vizcarrondo F, Chen J, Turner PK, Chow KH, Tai DF, Ilaria R. An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. Invest New Drugs. 2015 Feb; 33(1):148-58.
Score: 0.095
-
Witta SE, Jotte RM, Konduri K, Neubauer MA, Spira AI, Ruxer RL, Varella-Garcia M, Bunn PA, Hirsch FR. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol. 2012 Jun 20; 30(18):2248-55.
Score: 0.080
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|